A medical cosmetology skin wound dressing and a preparation process thereof

Abstract

This invention relates to the field of dressing technology, specifically to a medical aesthetic skin wound dressing and its preparation process. The preparation process of a medical aesthetic skin wound dressing includes: preparation of an antibacterial repair agent, preparation of a modified graphene oxide solution, preparation of modified carboxymethyl chitosan, and preparation of a wound hydrogel dressing. The dressing of this invention incorporates an antibacterial repair agent with a conjugated microporous network structure, providing dual potent antibacterial effects through physical confinement and chemical action, creating a sterile microenvironment for wound repair; it uses sericin-hydroxypropyl cellulose modified graphene oxide to solve problems of poor dispersibility and insufficient compatibility, enhancing moisturizing and cell repair activity; and it uses tetramethylolphosphonium sulfate as a crosslinking agent to construct a hydrogel framework, locking in components such as ε-polylysine hydrochloride, resulting in multi-component synergistic antibacterial action and promotion of epidermal regeneration, precisely meeting the needs of delicate, rapid, and scarless healing of medical aesthetic wounds.

Description

Technical Field

[0001] This invention relates to the field of dressing technology, specifically to a medical aesthetic skin wound dressing and its preparation process. Background Technology

[0002] With the rapid development of the medical aesthetics industry, medical aesthetic procedures such as laser therapy, injectable cosmetics, and minimally invasive plastic surgery are becoming increasingly popular. The skin wounds created by these procedures are characterized by their fineness, superficiality, severe damage to the skin barrier, and sensitivity and irritation. Moreover, consumers have extremely stringent requirements for wound healing. They not only need to quickly control wound infection and relieve redness and inflammation, but also need to achieve gentle wound repair, rapid healing, and no scarring, which meets the core needs of "refined care and scarless recovery" for medical aesthetic wounds.

[0003] The healing process of skin wounds is influenced by multiple factors, including infection, the wound microenvironment, and dressing compatibility. Among these, infection is one of the main causes of delayed healing, redness, swelling, inflammation, and scar hyperplasia after cosmetic procedures. Post-cosmetic procedures, the wound is in an "unprotected" state, with impaired skin barrier function, making it susceptible to invasion by common pathogens such as Staphylococcus aureus. Ordinary cosmetic repair products often have issues such as excessive total bacterial counts and preservative irritation, easily leading to wound infection and scarring, and failing to meet medical sterility requirements. While traditional medical wound dressings offer some protection, their compatibility with the delicate and sensitive wounds of cosmetic procedures is poor, presenting numerous technical challenges and failing to simultaneously meet multiple needs such as antibacterial properties, moisturizing, repair, and low irritation.

[0004] Currently, most medical aesthetic wound dressings use a single antibacterial ingredient or a single antibacterial mechanism. They either rely solely on physical barriers to achieve passive antibacterial action or rely solely on chemical action to kill bacteria. They lack the synergistic effect of physical confinement and efficient chemical sterilization, resulting in limited antibacterial efficacy and poor long-term effectiveness. At the same time, some antibacterial agents have problems such as poor water solubility and poor biocompatibility, which can easily irritate sensitive wounds. They also cannot simultaneously achieve antibacterial and biological repair functions, and cannot create a favorable sterile microenvironment for the proliferation of skin fibroblasts and the growth of granulation tissue, making it difficult to shorten the postoperative wound healing period.

[0005] Furthermore, while traditional gauze dressings offer basic wound protection, are soft, and inexpensive, their absorption capacity is limited. Once soaked, bacteria can easily invade the wound, leading to infection and complications such as redness and inflammation. Simultaneously, their poor water retention capacity fails to provide a stable, moist healing environment, easily causing dehydration and peeling, significantly prolonging the wound healing period. While existing hydrocolloid and hydrogel dressings offer improved water retention, their antibacterial properties are limited, and they lack targeted anti-inflammatory and repairing components, making it difficult to quickly alleviate postoperative redness and inflammation, failing to meet the core need for rapid recovery of cosmetic wounds. Additionally, traditional gauze dressings adhere heavily to wound exudate, easily pulling on scabs and newly formed tissue during dressing changes, causing secondary mechanical damage. This not only increases patient suffering but may also delay wound healing, lead to pigmentation, or even scarring, contradicting the original intention of scarless cosmetic repair.

[0006] Therefore, developing a medical aesthetic skin wound dressing and its preparation process that can effectively shorten the postoperative wound healing cycle, reduce complications such as redness and inflammation, block bacterial invasion, reduce dressing adhesion to the wound, create a good microenvironment for rapid and scarless healing of medical aesthetic wounds, and significantly improve dressing adaptability and repair effect has become an urgent technical problem to be solved in the field of medical aesthetic dressing technology, and has important practical significance and application value. Summary of the Invention

[0007] In view of the shortcomings of the existing technology, the purpose of this invention is to provide a skin wound dressing for medical aesthetics and its preparation process.

[0008] This invention provides a process for preparing a skin wound dressing for medical aesthetics, comprising: S1: Preparation of antibacterial repair agent; Using 1,3,5-triethynylbenzene and 2,5-dibromopyrimidine as raw materials, a mixed solvent of N,N-dimethylformamide and triethylamine and a catalyst were added. The mixture was stirred at a constant temperature under nitrogen protection, filtered, washed and dried to obtain an intermediate product. The intermediate product was then dissolved in acetonitrile, refluxed with iodomethane, washed and dried under vacuum to obtain an antibacterial repair agent. S2: Preparation of modified graphene oxide solution; Silkworm cocoons were boiled in sodium carbonate solution, centrifuged, dialyzed and freeze-dried to obtain sericin modifier; graphene oxide was dispersed in deionized water to obtain graphene oxide aqueous dispersion, which was then reacted with hydroxypropyl cellulose aqueous solution and sericin modifier at room temperature to obtain modified graphene oxide solution. S3: Preparation of modified carboxymethyl chitosan; First, a carboxymethyl chitosan aqueous solution of a specific concentration was prepared. Then, L-arginine was dissolved in an acetic acid aqueous solution, and NHS and EDC were added to adjust the pH value to obtain a mixture. The mixture was reacted with the carboxymethyl chitosan aqueous solution at a constant temperature and stirred. After dialysis and freeze-drying, modified carboxymethyl chitosan was obtained. S4: Preparation of hydrogel dressings for wounds; Modified carboxymethyl chitosan solution and ε-polylysine hydrochloride aqueous solution were prepared separately. The two were then mixed with antibacterial repair agent and modified graphene oxide solution. Finally, tetrahydroxymethyl phosphonium sulfate aqueous solution was added and oscillated to prepare a wound hydrogel dressing.

[0009] As a preferred aspect, S1: the preparation of the antibacterial repair agent specifically includes the following steps: S1.1: Add 15-20 parts by weight of 1,3,5-triethynylbenzene and 35-40 parts by weight of 2,5-dibromopyrimidine to a mixed solvent of 100-120 parts by weight of N,N-dimethylformamide and triethylamine, then add 2-3 parts by weight of tetrakis(triphenylphosphine)palladium and 1-2 parts by weight of copper iodide, stir and mix to obtain a mixed solution; S1.2: The mixed solution was stirred under nitrogen protection at 80-85℃ and 300-500rpm for 48-50h. After the reaction was completed, it was cooled to room temperature, then filtered, and the precipitate was washed with anhydrous ethanol 3-5 times. Finally, it was dried in a drying oven at 60-70℃ for 20-24h to obtain the intermediate product. S1.3: Add 20-30 parts by weight of intermediate product to 200-230 parts by weight of acetonitrile, then ultrasonically disperse for 20-30 min, then add 5-8 parts by weight of iodomethane, and then reflux at 80-85℃ for 36-40 h. After the reaction is complete, cool to room temperature, wash with ethanol 3-5 times, and finally vacuum dry to obtain antibacterial repair agent.

[0010] As a preferred aspect, the volume ratio of N,N-dimethylformamide and triethylamine in step S1.1 is 1:1.

[0011] As a preferred aspect, S2: the preparation of the modified graphene oxide solution specifically includes the following steps: S2.1: Cut 10-15 parts by weight of silkworm cocoons into small pieces and add them to 40-50 parts by weight of 0.5wt% sodium carbonate solution. Boil for 60-70 minutes, then filter. Centrifuge the filtered solution at 10000-12000 rpm for 10-12 minutes to obtain the supernatant. Dialyze the supernatant using a regenerated cellulose dialysis bag with a molecular weight cutoff of 14kDa for 3-4 days, and then freeze-dry to obtain the sericin modifier. S2.2: Add 10-12 parts by weight of graphene oxide to 100-120 parts by weight of deionized water, then stir magnetically at 300-500 rpm for 20-30 min, and then disperse ultrasonically for 20-30 min to obtain an aqueous dispersion of graphene oxide. S2.3: Add 5-8 parts by weight of hydroxypropyl cellulose to 20-30 parts by weight of deionized water, stir and mix for 20-30 minutes, then add graphene oxide aqueous dispersion, then add 2-3 parts by weight of sericin modifier, and then stir and react at room temperature for 6-8 hours to obtain modified graphene oxide solution.

[0012] As a preferred aspect, S3: the preparation of modified carboxymethyl chitosan specifically includes the following steps: S3.1: At room temperature, add carboxymethyl chitosan to deionized water while stirring at 1200-1500 rpm, and stir for 20-30 min to obtain a 1-2 wt% carboxymethyl chitosan aqueous solution; S3.2: Dissolve 1-2 parts by weight of L-arginine in 10-12 parts by weight of acetic acid aqueous solution, then add 0.5-0.6 parts by weight of NHS and 1-1.2 parts by weight of EDC, maintain the pH at 6-6.2, stir and mix for 20-30 minutes to obtain a mixture solution; S3.3: Add 50-60 parts by weight of 1-2 wt% carboxymethyl chitosan aqueous solution to the mixture solution, then stir the reaction at pH 6-6.2 for 20-24 h, then dialyze with deionized water for 4-5 days, and finally freeze-dry for 20-24 h to obtain modified carboxymethyl chitosan.

[0013] As a preferred aspect, the concentration of the acetic acid aqueous solution in step S3.2 is 1-1.2% (v / v).

[0014] As a preferred aspect, S4: the preparation of the wound hydrogel dressing specifically includes the following steps: S4.1: At room temperature, add 2-3 parts by weight of modified carboxymethyl chitosan to 30-40 parts by weight of deionized water, stir and mix at 200-300 rpm for 20-30 min to obtain a modified carboxymethyl chitosan solution, add 1-2 parts by weight of ε-polylysine hydrochloride to 100-120 parts by weight of deionized water, stir and mix at 200-300 rpm for 20-30 min to obtain an aqueous solution of ε-polylysine hydrochloride; S4.2: Mix 6-8 parts by weight of modified carboxymethyl chitosan solution, 3-5 parts by weight of ε-polylysine hydrochloride aqueous solution, 0.3-0.5 parts by weight of antibacterial repair agent and 1-2 parts by weight of modified graphene oxide solution, then stir at 1000-1200 rpm for 1-2 min, then add 1-2 parts by weight of 1 wt% tetrahydroxymethylphosphonium sulfate aqueous solution, and shake to mix for 1-2 min to obtain wound hydrogel dressing.

[0015] As a preferred aspect, the 1wt% tetrahydroxymethylphosphonium sulfate aqueous solution in step S4.2 is specifically obtained by adding 1-2 parts by weight of tetrahydroxymethylphosphonium sulfate to deionized water and stirring and mixing at 200-300 rpm for 20-30 min to obtain a 1wt% tetrahydroxymethylphosphonium sulfate aqueous solution.

[0016] The present invention also provides a skin wound dressing for medical aesthetics, which is prepared by any of the preparation processes of a skin wound dressing for medical aesthetics described in any one of the claims.

[0017] The present invention has the following advantages: 1. This invention incorporates an antibacterial repair agent into the dressing. This agent, through molecular structure design, possesses a conjugated microporous network structure, combining highly efficient antibacterial properties with biorepair activity. It exhibits a strong inhibitory effect on pathogenic bacteria commonly found in post-cosmetic surgery skin wounds. The microporous network structure of this polymer gives it a high specific surface area, effectively adsorbing bacteria and metabolites in wound exudate. Through physical confinement, it restricts bacterial diffusion and colonization, and adsorbs and deprives bacteria of the nutrients necessary for their growth, thus physically blocking the source of infection and preventing the spread of post-operative redness and inflammation. The pyrimidine ring in the molecular backbone of the antibacterial repair agent acts as a hydrophobic nitrogen-containing heterocycle. It can insert into the lipid bilayer of bacterial cell membranes through hydrophobic interactions, disrupting the integrity and fluidity of the membrane structure, causing leakage of bacterial contents, and achieving rapid killing of wound bacteria. Furthermore, the introduction of quaternary ammonium salt groups, after modification with iodomethane, significantly improves the water solubility and biocompatibility of the antibacterial repair agent. Its good water dispersibility and biocompatibility can effectively control wound infection, creating a sterile and favorable microenvironment for the proliferation of skin fibroblasts and the growth of granulation tissue, thereby shortening the postoperative wound healing cycle and reducing complications such as redness and inflammation, meeting the core needs of precise repair and rapid recovery of medical aesthetic wounds.

[0018] 2. The dual modification of sericin and hydroxypropyl cellulose in this invention effectively solves the core problems of poor dispersibility, poor compatibility with dressing matrix, and insufficient biocompatibility of traditional graphene oxide. The two work synergistically to achieve functional complementarity, meeting the needs of gentle repair and efficient care for medical and cosmetic wounds. Hydroxypropyl cellulose can break the van der Waals forces between graphene oxide sheets through hydrogen bonding and steric hindrance effects, preventing their aggregation and ensuring that graphene oxide is evenly distributed in the dressing, avoiding excessive local concentration that may irritate sensitive wounds, thus laying the foundation for subsequent function. The natural sericin modifier endows graphene oxide with excellent biocompatibility, reducing irritation to sensitive wounds after medical and cosmetic procedures. At the same time, its hydrophilic groups and active sites can improve the moisturizing performance of the dressing, promote the adhesion and proliferation of epidermal cells and fibroblasts, and help the epidermis regenerate. The two work together to achieve an integrated "dispersion-compatibility-repair" process. Hydroxypropyl cellulose enhances the binding force between graphene oxide and the dressing matrix, improving the mechanical stability of the hydrogel dressing. Meanwhile, the bioactivity of sericin strengthens the repair effect. The layered structure of graphene oxide enhances the density of the hydrogel network. Combined with the moisturizing properties of the hydrogel matrix, it forms a stable wound protection barrier, preventing bacterial invasion. The added dual-modified graphene oxide reduces the adhesion between the dressing and the wound, reducing secondary damage during dressing changes. At the same time, it locks in wound moisture and prevents skin peeling, creating a favorable microenvironment for rapid and scarless healing of medical aesthetic wounds, significantly improving the compatibility and repair effect of the dressing.

[0019] 3. In this invention, tetramethylolphosphonium sulfate (TMS) serves as a highly efficient and mild crosslinking agent, rapidly reacting with the amino groups introduced by arginine-modified carboxymethyl chitosan to form a three-dimensional network hydrogel framework. This crosslinking system endows the dressing with a soft texture and excellent elasticity, allowing it to closely conform to various delicate wound shapes after cosmetic procedures, preventing edge lifting. Simultaneously, its strong structural stability effectively locks in active ingredients such as ε-polylysine hydrochloride and modified graphene oxide, providing structural support for long-term functional performance. The introduction of L-arginine further improves the material's hydrophilicity and biocompatibility. The dressing's high hydrophilicity allows the formation of a hydration layer on its surface, acting as a physical barrier to effectively prevent non-specific binding of polymeric materials in the dressing to wound cells or proteins, thereby achieving [the desired effect]. The modified carboxymethyl chitosan has an anti-adhesion effect. Arginine, an endogenous substance in the human body, enhances the water solubility and distribution of the modified chitosan, without causing significant immune rejection, thus reducing redness and infection. Furthermore, the added ε-polylysine hydrochloride, a natural antibacterial agent, achieves broad-spectrum and highly effective bactericidal action while exhibiting good biocompatibility, making it suitable for sensitive wounds. Its chemical bactericidal effect synergistically works with the physical antibacterial barrier of modified graphene oxide to reduce the invasion and proliferation of common postoperative pathogens such as Staphylococcus aureus, effectively preventing infection-induced redness and inflammation, and achieving long-lasting antibacterial control. In addition, the tissue repair activity of modified carboxymethyl chitosan, combined with the cell proliferation effect of sericin and the moisturizing properties of graphene oxide, accelerates fibroblast proliferation and epidermal regeneration, promoting rapid and scarless wound healing. Attached Figure Description

[0020] Figure 1 This is a flowchart illustrating the preparation process of the medical aesthetic skin wound dressing used in an embodiment of the present invention. Detailed Implementation

[0021] To enable those skilled in the art to better understand the technical solutions of this invention, the technical solutions of this invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of this invention.

[0022] Example 1: A preparation process for a skin wound dressing for medical aesthetics, see [link to example]. Figure 1 ,include: S1: Preparation of antibacterial repair agent S1.1: Add 15 parts by weight of 1,3,5-triethynylbenzene and 35 parts by weight of 2,5-dibromopyrimidine to a mixed solvent of 100 parts by weight of N,N-dimethylformamide and triethylamine, with a volume ratio of N,N-dimethylformamide to triethylamine of 1:1. Then add 2 parts by weight of tetrakis(triphenylphosphine)palladium and 1 part by weight of copper iodide, stir and mix to obtain a mixed solution. S1.2: The mixed solution was stirred at 80°C and 300 rpm for 48 h under nitrogen protection. After the reaction was completed, it was cooled to room temperature, then filtered, and the precipitate was washed three times with anhydrous ethanol. Finally, it was dried in a drying oven at 60°C for 20 h to obtain the intermediate product. S1.3: 20 parts by weight of intermediate product were added to 200 parts by weight of acetonitrile, then ultrasonically dispersed for 20 min, then 5 parts by weight of iodomethane were added, and the mixture was refluxed at 80 °C for 36 h. After the reaction was completed, the mixture was cooled to room temperature, washed three times with ethanol, and finally vacuum dried to obtain the antibacterial repair agent. S2: Preparation of modified graphene oxide solution S2.1: Cut 10 parts by weight of silkworm cocoons into pieces and add them to 40 parts by weight of 0.5 wt% sodium carbonate solution. Boil for 60 min, then filter. Centrifuge the filtered solution at 10,000 rpm for 10 min to obtain the supernatant. Dialyze the supernatant using a regenerated cellulose dialysis bag with a molecular weight cutoff of 14 kDa for 3 days, and then freeze-dry to obtain the sericin modifier. S2.2: Add 10 parts by weight of graphene oxide to 100 parts by weight of deionized water, then stir magnetically at 300 rpm for 20 min, and then sonicate for 20 min to obtain an aqueous dispersion of graphene oxide. S2.3: Add 5 parts by weight of hydroxypropyl cellulose to 20 parts by weight of deionized water, stir and mix for 20 min, then add graphene oxide aqueous dispersion, then add 2 parts by weight of sericin modifier, and then stir and react at room temperature for 6 h to obtain modified graphene oxide solution. S3: Preparation of modified carboxymethyl chitosan S3.1: At room temperature, add carboxymethyl chitosan to deionized water with stirring at 1200 rpm and stir for 20 min to obtain a 1 wt% carboxymethyl chitosan aqueous solution; S3.2: Dissolve 1 part by weight of L-arginine in 10 parts by weight of 1% (v / v) acetic acid aqueous solution, then add 0.5 parts by weight of NHS and 1 part by weight of EDC, maintain the pH at 6, stir and mix for 20 min to obtain a mixture solution; S3.3: Add 50 parts by weight of 1 wt% carboxymethyl chitosan aqueous solution to the mixture solution, then stir the reaction at pH 6 for 20 h, then dialyze with deionized water for 4 days, and finally freeze dry for 20 h to obtain modified carboxymethyl chitosan. S4: Preparation of hydrogel dressings for wounds S4.1: At room temperature, add 2 parts by weight of modified carboxymethyl chitosan to 30 parts by weight of deionized water and stir at 200 rpm for 20 min to obtain a modified carboxymethyl chitosan solution. Add 1 part by weight of ε-polylysine hydrochloride to 100 parts by weight of deionized water and stir at 200 rpm for 20 min to obtain an aqueous solution of ε-polylysine hydrochloride. S4.2: Mix 6 parts by weight of modified carboxymethyl chitosan solution, 3 parts by weight of ε-polylysine hydrochloride aqueous solution, 0.3 parts by weight of antibacterial repair agent and 1 part by weight of modified graphene oxide solution, then stir at 1000 rpm for 1 min, then add 1 part by weight of 1 wt% tetrahydroxymethylphosphonium sulfate aqueous solution, shake and mix for 1 min to obtain wound hydrogel dressing.

[0023] Example 2: A preparation process for a skin wound dressing for medical aesthetics, see [link to example]. Figure 1 ,include: S1: Preparation of antibacterial repair agent S1.1: Add 20 parts by weight of 1,3,5-triethynylbenzene and 40 parts by weight of 2,5-dibromopyrimidine to a mixed solvent of 120 parts by weight of N,N-dimethylformamide and triethylamine, with a volume ratio of N,N-dimethylformamide and triethylamine of 1:1. Then add 3 parts by weight of tetrakis(triphenylphosphine)palladium and 2 parts by weight of copper iodide, stir and mix to obtain a mixed solution. S1.2: The mixed solution was stirred at 85°C and 500 rpm for 50 h under nitrogen protection. After the reaction was completed, it was cooled to room temperature, then filtered, and the precipitate was washed 5 times with anhydrous ethanol. Finally, it was dried in a drying oven at 70°C for 24 h to obtain the intermediate product. S1.3: 30 parts by weight of intermediate product were added to 230 parts by weight of acetonitrile, then ultrasonically dispersed for 30 min, then 8 parts by weight of iodomethane were added, and then refluxed at 85°C for 40 h. After the reaction was completed, the mixture was cooled to room temperature, washed 5 times with ethanol, and finally vacuum dried to obtain the antibacterial repair agent. S2: Preparation of modified graphene oxide solution S2.1: Cut 15 parts by weight of silkworm cocoons into pieces and add them to 50 parts by weight of 0.5wt% sodium carbonate solution. Boil for 70 minutes, then filter. Centrifuge the filtered solution at 12000 rpm for 12 minutes to obtain the supernatant. Dialyze the supernatant using a regenerated cellulose dialysis bag with a molecular weight cutoff of 14 kDa for 4 days, and then freeze-dry to obtain the sericin modifier. S2.2: Add 12 parts by weight of graphene oxide to 120 parts by weight of deionized water, then stir magnetically at 500 rpm for 30 min, and then sonicate for 30 min to obtain an aqueous dispersion of graphene oxide. S2.3: Add 8 parts by weight of hydroxypropyl cellulose to 30 parts by weight of deionized water, stir and mix for 30 min, then add graphene oxide aqueous dispersion, then add 3 parts by weight of sericin modifier, and then stir and react at room temperature for 8 h to obtain modified graphene oxide solution. S3: Preparation of modified carboxymethyl chitosan S3.1: At room temperature, add carboxymethyl chitosan to deionized water with stirring at 1500 rpm and stir for 30 min to obtain a 2 wt% carboxymethyl chitosan aqueous solution; S3.2: Dissolve 2 parts by weight of L-arginine in 12 parts by weight of 1-1.2% (v / v) aqueous acetic acid solution, then add 0.6 parts by weight of NHS and 1.2 parts by weight of EDC, maintain the pH at 6.2, stir and mix for 30 min to obtain a mixture solution; S3.3: Add 60 parts by weight of 2wt% carboxymethyl chitosan aqueous solution to the mixture solution, then stir the reaction at pH 6.2 for 24 h, then dialyze with deionized water for 5 days, and finally freeze-dry for 24 h to obtain modified carboxymethyl chitosan. S4: Preparation of hydrogel dressings for wounds S4.1: At room temperature, add 3 parts by weight of modified carboxymethyl chitosan to 40 parts by weight of deionized water and stir at 300 rpm for 30 min to obtain a modified carboxymethyl chitosan solution. Add 2 parts by weight of ε-polylysine hydrochloride to 120 parts by weight of deionized water and stir at 300 rpm for 30 min to obtain an aqueous solution of ε-polylysine hydrochloride. S4.2: Mix 8 parts by weight of modified carboxymethyl chitosan solution, 5 parts by weight of ε-polylysine hydrochloride aqueous solution, 0.5 parts by weight of antibacterial repair agent and 2 parts by weight of modified graphene oxide solution, then stir at 1200 rpm for 2 min, then add 2 parts by weight of 1 wt% tetrahydroxymethylphosphonium sulfate aqueous solution, shake and mix for 2 min to obtain wound hydrogel dressing.

[0024] Example 3: A preparation process for a skin wound dressing for medical aesthetics, see [link to example]. Figure 1 ,include: S1: Preparation of antibacterial repair agent S1.1: Add 17.5 parts by weight of 1,3,5-triethynylbenzene and 37.5 parts by weight of 2,5-dibromopyrimidine to a mixed solvent of 110 parts by weight of N,N-dimethylformamide and triethylamine, with a volume ratio of N,N-dimethylformamide to triethylamine of 1:1. Then add 2.5 parts by weight of tetrakis(triphenylphosphine)palladium and 1.5 parts by weight of copper iodide, stir and mix to obtain a mixed solution. S1.2: The mixed solution was stirred at 82.5℃ and 400rpm for 49h under nitrogen protection. After the reaction was completed, it was cooled to room temperature, then filtered, and the precipitate was washed 4 times with anhydrous ethanol. Finally, it was dried in a drying oven at 65℃ for 22h to obtain the intermediate product. S1.3: 25 parts by weight of intermediate product were added to 215 parts by weight of acetonitrile, then ultrasonically dispersed for 25 min, then 6.5 parts by weight of iodomethane were added, and the mixture was refluxed at 82.5 for 38 h. After the reaction was completed, the mixture was cooled to room temperature, washed 4 times with ethanol, and finally vacuum dried to obtain the antibacterial repair agent. S2: Preparation of modified graphene oxide solution S2.1: 12.5 parts by weight of silkworm cocoons were chopped and added to 45 parts by weight of 0.5 wt% sodium carbonate solution. The solution was boiled for 65 min and then filtered. The filtered solution was centrifuged at 11,000 rpm for 11 min to obtain the supernatant. The supernatant was dialyzed for 3.5 days using a regenerated cellulose dialysis bag with a molecular weight cutoff of 14 kDa and then freeze-dried to obtain the sericin modifier. S2.2: 11 parts by weight of graphene oxide were added to 110 parts by weight of deionized water, and then the mixture was magnetically stirred at 400 rpm for 25 min, followed by ultrasonic dispersion for 25 min to obtain an aqueous dispersion of graphene oxide. S2.3: Add 6.5 parts by weight of hydroxypropyl cellulose to 25 parts by weight of deionized water, stir and mix for 25 min, then add graphene oxide aqueous dispersion, then add 2.5 parts by weight of sericin modifier, and then stir and react at room temperature for 7 h to obtain modified graphene oxide solution. S3: Preparation of modified carboxymethyl chitosan S3.1: At room temperature, carboxymethyl chitosan was added to deionized water under stirring at 1350 rpm and stirred for 25 min to obtain a 1.5 wt% carboxymethyl chitosan aqueous solution. S3.2: Dissolve 1.5 parts by weight of L-arginine in 11 parts by weight of 1.1% (v / v) aqueous acetic acid solution, then add 0.55 parts by weight of NHS and 1.1 parts by weight of EDC, maintain the pH at 6.1, stir and mix for 25 min to obtain a mixture solution; S3.3: Add 55 parts by weight of 1.5 wt% carboxymethyl chitosan aqueous solution to the mixture solution, then stir the reaction at pH 6.1 for 22 h, then dialyze with deionized water for 4.5 days, and finally freeze dry for 22 h to obtain modified carboxymethyl chitosan. S4: Preparation of hydrogel dressings for wounds S4.1: At room temperature, 2.5 parts by weight of modified carboxymethyl chitosan were added to 35 parts by weight of deionized water and stirred at 250 rpm for 25 min to obtain a modified carboxymethyl chitosan solution. 1.5 parts by weight of ε-polylysine hydrochloride were added to 110 parts by weight of deionized water and stirred at 250 rpm for 25 min to obtain an aqueous solution of ε-polylysine hydrochloride. S4.2: Mix 7 parts by weight of modified carboxymethyl chitosan solution, 4 parts by weight of ε-polylysine hydrochloride aqueous solution, 0.4 parts by weight of antibacterial repair agent and 1.5 parts by weight of modified graphene oxide solution, then stir at 1100 rpm for 1.5 min, then add 1.5 parts by weight of 1 wt% tetrahydroxymethylphosphonium sulfate aqueous solution, shake and mix for 1.5 min to obtain wound hydrogel dressing.

[0025] Comparative Example 1 differs from Example 1 in that the antibacterial repair agent in steps S1 and S4.2 is removed, while the remaining steps remain unchanged in preparing the wound hydrogel dressing. This is referred to as Comparative Example 1.

[0026] Comparative Example 2 differs from Example 1 in that step S2.1 is removed, and the sericin modifier in step S2.3 is replaced with an equal amount of hydroxypropyl cellulose, while the remaining steps remain unchanged in preparing the wound hydrogel dressing. This is referred to as Comparative Example 2.

[0027] Comparative Example 3 differs from Example 1 in that the hydroxypropyl cellulose in step S2.3 is replaced with an equal amount of sericin modifier, while the other steps remain unchanged in preparing the wound hydrogel dressing. This is referred to as Comparative Example 3.

[0028] Comparative Example 4 differs from Example 1 in that step S3 is removed, and the modified carboxymethyl chitosan in step S4.1 is replaced with an equal amount of carboxymethyl chitosan, while the remaining steps remain unchanged in preparing the wound hydrogel dressing. This is referred to as Comparative Example 4.

[0029] Comparative Example 5 differs from Example 1 in that it is a dressing from Kobayashi Pharmaceutical Co., Ltd., and is referred to as Comparative Example 5.

[0030] Healthy male Wistar rats were selected and randomly divided into groups of 10 rats each. After anesthetizing the rats, their backs were shaved and disinfected. A circular full-thickness skin defect with a diameter of 1.5 cm was created using a punch. The dressings of each group were then applied to the wounds and fixed with sterile gauze and bandages. The dressings were changed once a day.

[0031] Wound area was recorded on postoperative days 0, 7, and 10. Wound healing rate was then calculated for each rat: Wound healing rate (%) = (Initial wound area - Wound area on day n) / Initial wound area × 100%. The average wound healing rate (%) for each group was then calculated. Results are shown in Table 1. Adhesion and redness / swelling were observed during dressing changes. Results are also shown in Table 1.

[0032] Table 1. Measurement results of Examples 1-3 and Comparative Examples 1-5 7-day wound healing rate (%) 10-day wound healing rate (%) Adhesions and redness Example 1 81.34 98.85 No adhesions, slight redness and swelling on day 7, no redness and swelling on day 10 Example 2 82.98 99.54 No adhesions, slight redness and swelling on day 7, no redness and swelling on day 10 Example 3 81.75 99.13 No adhesions, slight redness and swelling on day 7, no redness and swelling on day 10 Comparative Example 1 52.67 76.43 Almost no adhesions, noticeable redness and swelling on the 7th day, and slight redness and swelling still present on the 10th day. Comparative Example 2 63.21 84.56 Mild adhesions, moderate redness and swelling on day 7, and slight redness and swelling on day 10. Comparative Example 3 60.47 82.37 Mild adhesions, moderate redness and swelling on day 7, and slight redness and swelling on day 10. Comparative Example 4 58.92 80.14 Obvious adhesions, moderate redness and swelling on day 7, and mild redness and swelling on day 10. Comparative Example 5 71.25 90.68 Slight adhesions, slight redness and swelling on day 7, no redness and swelling on day 10. As can be seen from the data in Table 1, the wound healing rate of Comparative Example 1 of the present invention is significantly lower than that of the Example, indicating that the antibacterial repair agent added in the present invention can shorten the postoperative wound healing cycle and reduce complications such as redness and swelling. As can be seen from the data of Comparative Examples 2-3, the use of sericin-hydroxypropyl cellulose dual-modified graphene oxide can effectively improve the repair effect and promote wound healing. As can be seen from the data of Comparative Example 4, the introduction of arginine-modified carboxymethyl chitosan in the present invention can reduce redness and swelling and promote wound healing. As can be seen from the data of Comparative Example 5, the dressing prepared in the present invention can shorten the postoperative wound healing cycle and reduce complications such as redness and swelling, meeting the core needs of fine repair and rapid recovery of medical aesthetic wounds.

[0033] The antibacterial properties of the dressings prepared in Examples 1-3 and Comparative Example 1 were determined: The antibacterial activity of the dressing against Escherichia coli and Staphylococcus aureus was tested using the agar diffusion method: 100 μL of a 10... 7 A CFU / mL bacterial suspension was evenly spread onto sterilized LB solid medium. Each group of dressings (8 mm diameter discs) was then placed on the surface of the medium and incubated at 37°C for 24 h. The diameter of the inhibition zone was measured. The measurement was performed three times, and the average value was taken. The results are shown in Table 2.

[0034] Table 2. Results of antibacterial performance testing of Examples 1-3 and Comparative Example 1 Diameter of the inhibition zone of Escherichia coli (mm) Diameter of the inhibition zone of Staphylococcus aureus (mm) Example 1 13.2 14.5 Example 2 13.9 15.2 Example 3 13.5 14.9 Comparative Example 1 8.3 8.5 As can be seen from the data in Table 2, the antibacterial repair agent added in this invention has a strong inhibitory effect on pathogenic bacteria commonly found in skin wounds after medical aesthetic surgery, which can significantly improve the antibacterial effect, achieve rapid wound repair, and avoid infection.

[0035] The dressings prepared in Examples 1-3 and Comparative Example 3 were subjected to mechanical property testing in accordance with the "Pharmaceutical Industry Standard of the People's Republic of China (YY / T1435-2016)". The tests were conducted three times and the average value was taken. The test results are shown in Table 3.

[0036] Table 3. Results of Elongation at Break Measurement in Examples 1-3 and Comparative Example 3 Elongation at break (%) Example 1 82.3 Example 2 83.4 Example 3 82.7 Comparative Example 3 71.4 As can be seen from the data in Table 3, hydroxypropyl cellulose modification can enhance the bonding force between graphene oxide and the dressing matrix, giving it good fracture resistance and improving the mechanical stability of the hydrogel dressing.

[0037] The dressings prepared in Examples 1-3 were subjected to cytotoxicity testing according to GB / T14233.2-2005, and the results showed that they were all non-toxic.

[0038] It should be understood that those skilled in the art can make improvements or modifications based on the above description, and all such improvements and modifications should fall within the protection scope of the appended claims. Parts not described in detail in this specification are prior art known to those skilled in the art.

Claims

1. A preparation process for a skin wound dressing for medical aesthetics, characterized in that, include: S1: Preparation of antibacterial repair agent; Using 1,3,5-triethynylbenzene and 2,5-dibromopyrimidine as raw materials, a mixed solvent of N,N-dimethylformamide and triethylamine and a catalyst were added. The mixture was stirred at a constant temperature under nitrogen protection, filtered, washed and dried to obtain an intermediate product. The intermediate product was then dissolved in acetonitrile, refluxed with iodomethane, washed and dried under vacuum to obtain an antibacterial repair agent. S2: Preparation of modified graphene oxide solution; Silkworm cocoons were boiled in sodium carbonate solution, centrifuged, dialyzed and freeze-dried to obtain sericin modifier; graphene oxide was dispersed in deionized water to obtain graphene oxide aqueous dispersion, which was then reacted with hydroxypropyl cellulose aqueous solution and sericin modifier at room temperature to obtain modified graphene oxide solution. S3: Preparation of modified carboxymethyl chitosan; First, a carboxymethyl chitosan aqueous solution of a specific concentration was prepared. Then, L-arginine was dissolved in an acetic acid aqueous solution, and NHS and EDC were added to adjust the pH value to obtain a mixture. The mixture was reacted with the carboxymethyl chitosan aqueous solution at a constant temperature and stirred. After dialysis and freeze-drying, modified carboxymethyl chitosan was obtained. S4: Preparation of hydrogel dressings for wounds; Modified carboxymethyl chitosan solution and ε-polylysine hydrochloride aqueous solution were prepared separately. The two were then mixed with antibacterial repair agent and modified graphene oxide solution. Finally, tetrahydroxymethyl phosphonium sulfate aqueous solution was added and oscillated to prepare a wound hydrogel dressing.

2. The preparation process of a medical aesthetic skin wound dressing according to claim 1, characterized in that, S1: The preparation of the antibacterial repair agent includes the following steps: S1.1: Add 15-20 parts by weight of 1,3,5-triethynylbenzene and 35-40 parts by weight of 2,5-dibromopyrimidine to a mixed solvent of 100-120 parts by weight of N,N-dimethylformamide and triethylamine, then add 2-3 parts by weight of tetrakis(triphenylphosphine)palladium and 1-2 parts by weight of copper iodide, stir and mix to obtain a mixed solution; S1.2: The mixed solution was stirred under nitrogen protection at 80-85℃ and 300-500rpm for 48-50h. After the reaction was completed, it was cooled to room temperature, then filtered, and the precipitate was washed with anhydrous ethanol 3-5 times. Finally, it was dried in a drying oven at 60-70℃ for 20-24h to obtain the intermediate product. S1.3: Add 20-30 parts by weight of intermediate product to 200-230 parts by weight of acetonitrile, then ultrasonically disperse for 20-30 min, then add 5-8 parts by weight of iodomethane, and then reflux at 80-85℃ for 36-40 h. After the reaction is complete, cool to room temperature, wash with ethanol 3-5 times, and finally vacuum dry to obtain antibacterial repair agent.

3. The preparation process of a medical aesthetic skin wound dressing according to claim 2, characterized in that, In step S1.1, the volume ratio of N,N-dimethylformamide to triethylamine is 1:

1.

4. The preparation process of a medical aesthetic skin wound dressing according to claim 1, characterized in that, S2: Preparation of modified graphene oxide solution, specifically including the following steps: S2.1: Cut 10-15 parts by weight of silkworm cocoons into small pieces and add them to 40-50 parts by weight of 0.5wt% sodium carbonate solution. Boil for 60-70 minutes, then filter. Centrifuge the filtered solution at 10000-12000 rpm for 10-12 minutes to obtain the supernatant. Dialyze the supernatant using a regenerated cellulose dialysis bag with a molecular weight cutoff of 14kDa for 3-4 days, and then freeze-dry to obtain the sericin modifier. S2.2: Add 10-12 parts by weight of graphene oxide to 100-120 parts by weight of deionized water, then stir magnetically at 300-500 rpm for 20-30 min, and then disperse ultrasonically for 20-30 min to obtain an aqueous dispersion of graphene oxide. S2.3: Add 5-8 parts by weight of hydroxypropyl cellulose to 20-30 parts by weight of deionized water, stir and mix for 20-30 minutes, then add graphene oxide aqueous dispersion, then add 2-3 parts by weight of sericin modifier, and then stir and react at room temperature for 6-8 hours to obtain modified graphene oxide solution.

5. The preparation process of a medical aesthetic skin wound dressing according to claim 1, characterized in that, S3: Preparation of modified carboxymethyl chitosan, specifically including the following steps: S3.1: At room temperature, add carboxymethyl chitosan to deionized water while stirring at 1200-1500 rpm, and stir for 20-30 min to obtain a 1-2 wt% carboxymethyl chitosan aqueous solution; S3.2: Dissolve 1-2 parts by weight of L-arginine in 10-12 parts by weight of acetic acid aqueous solution, then add 0.5-0.6 parts by weight of NHS and 1-1.2 parts by weight of EDC, maintain the pH at 6-6.2, stir and mix for 20-30 minutes to obtain a mixture solution; S3.3: Add 50-60 parts by weight of 1-2 wt% carboxymethyl chitosan aqueous solution to the mixture solution, then stir the reaction at pH 6-6.2 for 20-24 h, then dialyze with deionized water for 4-5 days, and finally freeze-dry for 20-24 h to obtain modified carboxymethyl chitosan.

6. The preparation process of a medical aesthetic skin wound dressing according to claim 5, characterized in that, In step S3.2, the concentration of the acetic acid aqueous solution is 1-1.2% (v / v).

7. The preparation process of a medical aesthetic skin wound dressing according to claim 1, characterized in that, S4: Preparation of wound hydrogel dressing, specifically including the following steps: S4.1: At room temperature, add 2-3 parts by weight of modified carboxymethyl chitosan to 30-40 parts by weight of deionized water, stir and mix at 200-300 rpm for 20-30 min to obtain a modified carboxymethyl chitosan solution, add 1-2 parts by weight of ε-polylysine hydrochloride to 100-120 parts by weight of deionized water, stir and mix at 200-300 rpm for 20-30 min to obtain an aqueous solution of ε-polylysine hydrochloride; S4.2: Mix 6-8 parts by weight of modified carboxymethyl chitosan solution, 3-5 parts by weight of ε-polylysine hydrochloride aqueous solution, 0.3-0.5 parts by weight of antibacterial repair agent and 1-2 parts by weight of modified graphene oxide solution, then stir at 1000-1200 rpm for 1-2 min, then add 1-2 parts by weight of 1 wt% tetrahydroxymethylphosphonium sulfate aqueous solution, and shake to mix for 1-2 min to obtain wound hydrogel dressing.

8. The preparation process of a medical aesthetic skin wound dressing according to claim 7, characterized in that, The 1wt% tetrahydroxymethylphosphonium sulfate aqueous solution in step S4.2 is specifically obtained by adding 1-2 parts by weight of tetrahydroxymethylphosphonium sulfate to deionized water and stirring and mixing at 200-300 rpm for 20-30 min to obtain a 1wt% tetrahydroxymethylphosphonium sulfate aqueous solution.

9. A medical aesthetic dressing for skin wounds, characterized in that, It is prepared by the preparation process of a medical aesthetic skin wound dressing as described in any one of claims 1-8.

Images